New insights on premature ejaculation: a review of definition, classification, prevalence and treatment.
There are ongoing debates about the definition, classification and prevalence of premature ejaculation (PE). The first evidence-based definition of PE was limited to heterosexual men with lifelong PE who engage in vaginal intercourse. Unfortunately, many patients with the complaint of PE do not meet these criteria. However, these men can be diagnosed as one of the PE subtypes, namely acquired PE, natural variable PE or premature-like ejaculatory dysfunction. Nevertheless, the validity of these subtypes has not yet been supported by evidence. The absence of a universally accepted PE definition and lack of standards for data acquisition have resulted in prevalence studies that have reported conflicting rates. The very high prevalence of 20%-30% is probably due to the vague terminology used in the definitions at the time when such surveys were conducted. Although many men may complain of PE when questioned for a population-based prevalence study, only a few of them will actively seek treatment for their complaint, even though most of these patients would define symptoms congruent with PE. The complaints of acquired PE patients may be more severe, whereas complaints of patients experiencing premature-like ejaculatory dysfunction seem to be least severe among men with various forms of PE. Although numerous treatment modalities have been proposed for management of PE, only antidepressants and topical anaesthetic creams have currently been proven to be effective. However, as none of the treatment modalities have been approved by the regulatory agencies, further studies must be carried to develop a beneficial treatment strategy for PE.
Tulane University, School of Medicine, Department of Urology, New Orleans, LA 70112, USA. egecanserefoglu@hotmail.com
Ege C
EC
Serefoglu
Theodore R
TR
Saitz
D000818:Animals; D001596:Benzylamines / Q000627:therapeutic use; D003075:Coitus; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D061686:Premature Ejaculation / Q000145:classification* / Q000453:epidemiology* / Q000628:therapy*; D015995:Prevalence; D011318:Prilocaine / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D012735:Sexual Dysfunction, Physiological / Q000175:diagnosis; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use
D001596:Benzylamines; D008012:Lidocaine; D009281:Naphthalenes; D010879:Piperazines; D011318:Prilocaine; D011687:Purines; D017367:Selective Serotonin Reuptake Inhibitors; D000068677:Sildenafil Citrate; D013450:Sulfones; C080598:dapoxetine